Aptamer

Jump to: navigation, search

WikiDoc Resources for

Aptamer

Articles

Most recent articles on Aptamer

Most cited articles on Aptamer

Review articles on Aptamer

Articles on Aptamer in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aptamer

Images of Aptamer

Photos of Aptamer

Podcasts & MP3s on Aptamer

Videos on Aptamer

Evidence Based Medicine

Cochrane Collaboration on Aptamer

Bandolier on Aptamer

TRIP on Aptamer

Clinical Trials

Ongoing Trials on Aptamer at Clinical Trials.gov

Trial results on Aptamer

Clinical Trials on Aptamer at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aptamer

NICE Guidance on Aptamer

NHS PRODIGY Guidance

FDA on Aptamer

CDC on Aptamer

Books

Books on Aptamer

News

Aptamer in the news

Be alerted to news on Aptamer

News trends on Aptamer

Commentary

Blogs on Aptamer

Definitions

Definitions of Aptamer

Patient Resources / Community

Patient resources on Aptamer

Discussion groups on Aptamer

Patient Handouts on Aptamer

Directions to Hospitals Treating Aptamer

Risk calculators and risk factors for Aptamer

Healthcare Provider Resources

Symptoms of Aptamer

Causes & Risk Factors for Aptamer

Diagnostic studies for Aptamer

Treatment of Aptamer

Continuing Medical Education (CME)

CME Programs on Aptamer

International

Aptamer en Espanol

Aptamer en Francais

Business

Aptamer in the Marketplace

Patents on Aptamer

Experimental / Informatics

List of terms related to Aptamer

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Aptamers are oligonucleic acid or peptide molecules that bind a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist in riboswitches. Aptamers can be used for both basic research and clinical purposes as macromolecular drugs. Aptamers can be combined with ribozymes to self-cleave in the presence of their target molecule. These compound molecules have additional research, industrial and clinical applications.

More specifically, aptamers can be classified as:

  • DNA or RNA aptamers. They consist of (usually short) strands of oligonucleotides.
  • Peptide aptamers. They consist of a short variable peptide domain, attached at both ends to a protein scaffold.

RNA and DNA aptamers

Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection or equivalently, SELEX (systematic evolution of ligands by exponential enrichment) to bind to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues and organisms. Aptamers offer the utility for biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of the commonly used biomolecule, antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.

In 1990, two labs independently developed the technique of selection: the Gold lab, utilizing the term SELEX for their process of selecting RNA ligands against T4 DNA polymerase; and the Szostak lab, coining the term in vitro selection, selecting RNA ligands against various organic dyes. The Szostak lab also coined the term aptamer (from the Latin, aptus, meaning ‘to fit’) for these nucleic acid-based ligands. Two years later, the Szostak lab and Gilead Sciences, independent of one another, utilized in vitro selection schemes to evolve single stranded DNA ligands for organic dyes and human coagulant, thrombin, respectively. There does not appear to be any systematic differences between RNA and DNA aptamers, save the greater intrinsic chemical stability of DNA.

Interestingly enough, the notion of selection in vitro was actually preceded twenty-plus years prior when the infamous Sol Spiegelman utilized a Qbeta replication system as a way to evolve a self-replicating molecule. In addition, a year before the publishing of in vitro selection and SELEX, Gerald Joyce utilized a system that he termed ‘directed evolution’ to alter the cleavage activity of a ribozyme.

Over the course of the next sixteen years, many researchers have utilized aptamer selection as a means for application and discovery. In 2001, the process of in vitro selection was automated by the Ellington lab at the University of Texas at Austin, and at SomaLogic, Inc (Boulder, CO), reducing the duration of a selection experiment from six weeks to three days.

While the process of artificial engineering of nucleic acid ligands is highly interesting to biology and biotechnology, the notion of aptamers in the natural world had yet to be uncovered until 2002 when Ronald Breaker and his coworkers discovered a nucleic acid-based genetic regulatory element called a riboswitch that possesses similar molecular recognition properties to the artificially made aptamers. In addition to the discovery of a new mode of genetic regulation, this adds further credence to the notion of an ‘RNA World,’ a postulated stage in time in the origins of life on Earth.

Lately, a concept of smart aptamers, and smart ligands in general, has been introduced. It describes aptamers that are selected with pre-defined equilibrium (<math>K_{d}</math>), kinetic (<math>k_{off}</math> , <math>k_{on}</math>) and thermodynamic (ΔH, ΔS) parameters of aptamer-target interaction.

Recent developments in aptamer-based therapeutics have been rewarded in the form of the first aptamer-based drug approved by the U.S. Food and Drug Administration (FDA) in treatment for age-related macular degeneration (AMD), called Macugen offered by OSI Pharmaceuticals. In addition, Cambridge, MA - based Archemix (http://www.archemix.com) is leading the development of aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute diseases. ARC1779, its lead proprietary candidate, is a potent, selective, first-in-class antagonist of von Willebrand Factor (vWF). ARC1779 is being evaluated in patients diagnosed with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI). Phase I testing for ARC1779 was initiated in December 2006, and a Phase 2 study in ACS is planned to begin by the end of 2007.

Non-modified aptamers are cleared rapidly from the bloodstream, with a half-life of minutes to hours, mainly due to nuclease degradation and clearance from the body by the kidneys, a result of the aptamer's inherently low molecular weight. Unmodified aptamer applications currently focus on treating transient conditions such as blood clotting, or treating organs such as the eye where local delivery is possible. This rapid clearance can be an advantage in applications such as in vivo diagnostic imaging. An example is a tenascin-binding aptamer under development by Schering AG for cancer imaging. Several modifications, such as 2'-fluorine-substituted pyrimidines, polyethylene glycol (PEG) linkage, etc. (both of which are used in Macugen, an FDA-approved aptamer) are available to scientists with which to increase the half-life of aptamers easily to the day or even week time scale.

In addition to the development of aptamer-based therapeutics, many researchers such as the Ellington lab and the Boulder, CO-based SomaLogic have been developing diagnostic techniques for whole cell protein profiling called proteomics, and medical diagnostics for the distinction of disease versus healthy states.

As a resource for all in vitro selection and SELEX experiments, the Ellington lab has developed the Aptamer Database cataloging all published experiments. This is found at http://aptamer.icmb.utexas.edu/.

Peptide aptamers

Peptide aptamers are proteins that are designed to interfere with other protein interactions inside cells. They consist of a variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the peptide aptamer to levels comparable to an antibody's (nanomolar range).

The variable loop length is typically comprised of 10 to 20 amino acids, and the scaffold may be any protein which have good solubility and compacity properties. Currently, the bacterial protein Thioredoxin-A is the most used scaffold protein, the variable loop being inserted within the reducing active site, which is a -Cys-Gly-Pro-Cys- loop in the wild protein, the two Cysteines lateral chains being able to form a disulfide bridge.

Peptide aptamer selection can be made using different systems, but the most used is currently the yeast two-hybrid system.

Selection of Ligand Regulated Peptide Aptamers (LiRPAs) has been demonstrated. By displaying 7 amino acid peptides from a novel scaffold protein based on the trimeric FKBP-rapamycin-FRB structure, interaction between the randomized peptide and target molecule can be controlled by the small molecule Rapamycin or non-immunosuppressive analogs.

Use as Pharmacologic Agents

It should be noted that aptamers are electrostatically highly charged and can activate the complement resulting in anaphylactoid or anaphylactic reactions. The risk of allergic reactions may be minimized by slowing the infusion rate.

References

  • Ellington AD, Szostak JW, "In vitro selection of RNA molecules that bind specific ligands.", Nature, 1990 Aug 30;346(6287):818-22. PMID: 1697402
  • Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ, "Selection of single-stranded DNA molecules that bind and inhibit human thrombin.", Nature, 1992 Feb 6,355(6360):564-6 PMID: 1741036
  • Hoppe-Seyler F, Butz K "Peptide aptamers: powerful new tools for molecular medicine.", J Mol Med. 2000;78(8):426-30.PMID: 11097111
  • Carothers JM, Oestreich SC, Davis JH, Szostak JW, "Informational complexity and functional activity of RNA structures.", J Am Chem Soc. 2004 Apr 28;126(16):5130-7. PMID: 15099096
  • Cohen BA, Colas P, Brent R, "An artificial cell-cycle inhibitor isolated from a combinatorial library", PNAS 1998 Nov 24;95(24):14272-7. PMID: 9826690
  • Binkowski BF, Miller RA, Belshaw PJ, "Ligand Regulated Peptides: A general approach for selection of ligand regulated peptide-protein interactions" Chem & Biol. 2005 July, 12 (7):847-55.

PMID: 16039531

  • Sullenger BA, Gilboa E, "Emerging clinical applications of RNA" Nature 2002, 418:252-258.
  • Ng EW, Shima DT, Calias P, Cunningham ET, Jr., Guyer DR, Adamis AP, "Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease" Nat Rev Drug Discov 2006, 5:123-132.
  • Bunka, D.H.J. and Stockley, P.G. "Aptamers come of age—at last.", Nat. Rev. Microbiol. 2006 August;4(8):588-596 PMID: 16845429

External links


Navigation WikiDoc | WikiPatient | Up To Date Pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg